Sanofi to Sell 50% Stake in Consumer Healthcare Unit Opella to CD&R for €15 Billion

Gelonghui February 19 | Sanofi S.A. sold a 50% controlling stake in its consumer healthcare business, Opella, to private equity firm Clayton, Dubilier & Rice, LLC (CD&R). The terms of the deal remain unchanged from those previously disclosed and are expected to be completed as early as the second quarter of 2025. Sanofi initiated negotiations with CD&R regarding a potential sale in October 2024. Foreign media at the time reported that the transaction was valued at approximately €15 billion (approximately $16.4 billion). Opella, headquartered in France, markets over-the-counter medicines and vitamins, minerals, and supplements, managing 100 brands including Allegra, Doliprane, Novanight, Icy Hot, and Dulcolax. It oversees 13 production sites and four research and innovation centers.